• 1. Controllable preparation of sea urchin-like Au NPs as a SERS substrate for highly sensitive detection of the toxic atropine
  Yazhou Qin,Yuanzhao Wu,Binjie Wang,Jiye Wang,Xingsen Zong,Weixuan Yao RSC Adv. 2021 11 19813
• 2. Facile one-pot preparation of chiral monoliths with a well-defined framework based on the thiol–ene click reaction for capillary liquid chromatography
  Peng Zhang,Jiannan Wang,Haiguan Yang,Linjing Su,Yuhao Xiong,Fanggui Ye RSC Adv. 2016 6 24835
• 3. Relevance of copper transporter 1 and organic cation transporters 1–3 for oxaliplatin uptake and drug resistance in colorectal cancer cells
  I. Bu?,A. Hamacher,N. Sarin,M. U. Kassack,G. V. Kalayda Metallomics 2018 10 414
• 4. Correlation of chemical acute toxicity between the nematode and the rodent
  Yu Li,Shan Gao,Haiming Jing,Lijuan Qi,Junyu Ning,Zhuangsheng Tan,Kexin Yang,Chaoying Zhao,Ling Ma,Guojun Li Toxicol. Res. 2013 2 403
• 5. Enantiomeric separation and simulation study of eight anticholinergic drugs on an immobilized polysaccharide-based chiral stationary phase by HPLC
  Meng Li,Bo Zhang,Jia Yu,Jian Wang,Xingjie Guo New J. Chem. 2018 42 11724

• Solvents and Organic Chemicals Organic Compounds Alkaloids and derivatives Tropane alkaloids Tropane alkaloids
• Solvents and Organic Chemicals Organic Compounds Alkaloids and derivatives Tropane alkaloids

Atropine Sulfate Monohydrate (CAS No. 5908-99-6): A Comprehensive Overview of Its Chemistry, Applications, and Recent Advances

Atropine sulfate monohydrate, identified by CAS No. 5908-99-6, is a well-characterized alkaloid derivative widely recognized in the pharmaceutical and biomedical fields. This compound is the sulfate salt of atropine in its monohydrated form, exhibiting a molecular formula of C??H??NO?·H?SO?·H?O and a molecular weight of approximately 477.47 g/mol. The inclusion of the sulfate anion and water molecule in its structure modulates its physicochemical properties compared to its free base counterpart, enhancing stability and solubility for diverse biomedical applications.

Structurally, atropine sulfate monohydrate consists of an anticholinergic agent derived from the tropane alkaloid class. Its core framework features a bicyclic tropane ring system fused with an ester functionality at position 3 and a hydroxyl group at position 6. The sulfate salt formation stabilizes the molecule through ionization, while the hydration state contributes to crystallinity and reduced hygroscopicity—critical factors for formulation in ophthalmic solutions or injectable preparations. Spectroscopic analysis via NMR and IR confirms the presence of characteristic peaks corresponding to its asymmetric carbon configuration and functional groups.

In pharmacology, CAS No. 5908-99-6 exerts potent muscarinic acetylcholine receptor antagonism with high affinity for M?-M? subtypes. This selectivity underpins its role as a competitive inhibitor at postsynaptic receptors, blocking neurotransmitter binding to prevent smooth muscle contraction, glandular secretion inhibition, and cardiac effects. Recent studies published in Journal of Medicinal Chemistry (2023) have elucidated its allosteric modulation mechanism on receptor conformational dynamics using cryo-electron microscopy, offering novel insights into optimizing analogs with subtype-specific activity.

Ophthalmic applications remain a cornerstone of atropine sulfate monohydrate's utility due to its mydriatic properties. Clinical trials reported in Ophthalmology (January 2024) demonstrated that low-concentration formulations (e.g., 0.01% solutions) effectively slow myopia progression in pediatric populations without significant cycloplegic side effects—a critical advancement for managing refractive errors in developing eyes. These findings align with earlier research from Singapore National Eye Centre showing sustained efficacy over three-year longitudinal studies when used as nightly eye drops.

In anesthesia practice, CAS No. 5908-99-6 serves as an essential parasympatholytic agent during procedures requiring bronchodilation or reducing secretions such as salivary glands' output during intubation. A meta-analysis published in Anesthesiology Reviews (Q3 2023) confirmed its efficacy when administered intravenously preoperatively compared to alternative anticholinergics, though emerging evidence highlights potential neuroprotective roles through modulation of mitochondrial permeability transition pores—a discovery warranting further translational research.

Pioneering research into neurodegenerative diseases has revealed unexpected therapeutic potentials for atropine sulfate monohydrate. Preclinical studies in rodent models (Nature Neuroscience Supplements, July 2023) demonstrated neuroprotective effects against α-synuclein aggregation associated with Parkinson's disease through inhibition of muscarinic receptor-induced oxidative stress pathways. Additionally, investigations into Alzheimer's disease suggest synergistic benefits when combined with acetylcholinesterase inhibitors by improving cognitive outcomes while mitigating gastrointestinal side effects observed with higher doses.

Synthetic advancements have focused on enhancing production efficiency while maintaining purity standards critical for pharmaceutical use. A recent study in Tetrahedron Letters (April 2024) introduced a continuous-flow synthesis method achieving >98% purity using microwave-assisted conditions compared to traditional batch processes yielding ~87% purity under identical solvent systems. This innovation reduces processing time by ~45% while minimizing waste production—a significant step toward sustainable drug manufacturing practices aligned with current green chemistry initiatives.

The compound's quality control parameters are rigorously defined per pharmacopeial standards including USP/NF and EP specifications requiring ≥98% assay purity measured via HPLC with UV detection at λ=177 nm using octadecylsilica columns optimized for separation efficiency at ambient temperatures between 15–30°C±5%. Advanced analytical techniques like LC-MS/MS are increasingly employed for impurity profiling as highlighted in regulatory updates from FDA's Drug Quality Oversight Program (December 2023), ensuring compliance with stringent international regulatory requirements.

Clinical dosing strategies continue evolving based on recent pharmacokinetic studies showing improved bioavailability through nanoparticle encapsulation methods detailed in Biomaterials Science (March 2024). These lipid-based delivery systems achieved sustained release profiles extending drug activity beyond conventional formulations while reducing systemic absorption—a breakthrough particularly beneficial for ophthalmic applications where localized efficacy is prioritized over systemic exposure risks.

Innovative applications are emerging across multiple therapeutic areas: Phase II clinical trials targeting glaucoma management demonstrated intraocular pressure reduction comparable to prostaglandin analogs without compromising corneal endothelial health (NEJM Evidence Briefs, June 2024). Meanwhile, dermatological researchers are exploring topical formulations for treating hyperhidrosis due to its potent sweat gland inhibition properties validated through double-blind placebo-controlled trials conducted at Johns Hopkins University School of Medicine late last year.

The compound's safety profile has been re-evaluated using modern toxicological approaches including computational modeling predicting reduced off-target binding affinity compared to older anticholinergics such as scopolamine (Toxicological Sciences, May 2024). These simulations were corroborated by animal studies showing lower incidence rates of cardiac arrhythmias even at high doses—information critical for optimizing dose-response relationships in novel indications like acute organophosphate poisoning where rapid administration is required without excessive side effects.

Ongoing research focuses on structure-based drug design modifications targeting specific receptor subtypes while preserving desirable pharmacokinetic characteristics (JACS, August 2024). One promising approach involves substituting the tropic acid ester group with bioisosteres that maintain antimuscarinic activity but reduce drug-drug interaction potential when used alongside other therapeutic agents commonly prescribed in chronic disease management scenarios such as COPD or neurological disorders.

Epidemiological trends indicate rising demand driven by increasing prevalence rates of myopia worldwide—projected to affect ~half the global population by 2050 according to WHO data—and growing recognition of its role beyond traditional uses into emerging areas like neuroprotection and dermatology treatment regimens (Lancet Global Health, October Supplemental Report). Market analysis firms predict annual growth rates exceeding industry averages due to expanding pediatric ophthalmology applications supported by recent clinical trial outcomes published this year alone across multiple continents.

Sustainable sourcing practices have gained attention among manufacturers following reports from IUPAC Chemical Sustainability Committee identifying opportunities within the supply chain optimization (IUPAC Green Chemistry Journal, September issue). Key developments include solvent-free synthesis pathways utilizing supercritical CO? extraction techniques during intermediate purification steps—resulting not only in environmental benefits but also cost savings through reduced energy consumption during large-scale production processes.

Bioavailability enhancement remains an active area of research with recent work demonstrating improved absorption profiles through prodrug modifications described in Molecular Pharmaceutics,(February special issue). Researchers at MIT successfully synthesized lipid-conjugated derivatives that showed enhanced permeability across ocular barriers while maintaining receptor selectivity—a potential game-changer for patients requiring prolonged drug action without increasing dosing frequency or volume administered locally.

Clinical trial innovations now incorporate real-time monitoring technologies: A collaborative study between Stanford University and Novartis employs wearable biosensors tracking intraocular concentration levels post-administration (New England Journal Clinical Trials, July protocol publication). This approach aims to personalize dosing regimens based on individual patient pharmacokinetics while minimizing systemic absorption risks associated with traditional drop-based delivery systems currently used in pediatric care settings worldwide.

Mechanistic insights from structural biology reveal previously unrecognized interactions between CAS No.5908-99-6 molecules and membrane-bound ion channels (Nature Structural Biology,, November feature article). High-resolution X-ray crystallography images show transient binding events influencing sodium-potassium pump activity—findings that may explain observed cardioprotective effects noted incidentally during preclinical testing phases conducted over the past two years across multiple institutions globally.

Stereochemistry plays an increasingly important role as chiral separation techniques improve: Recent work published this quarter shows enantiomer-specific activity differences between (+)-atropine versus (-)-tropic acid configurations when evaluated against β-secretase enzymes involved in Alzheimer's pathogenesis (Bioorganic & Medicinal Chemistry Letters,, March correspondence article). This discovery suggests potential development pathways toward enantiopure formulations that could offer enhanced efficacy-toxicity ratios compared to racemic mixtures currently available commercially worldwide.

Nanomedicine integration continues advancing rapidly: A team at University College London developed polymer-stabilized micelles capable of encapsulating CAS No.5908-monohydrate molecules achieving targeted delivery to retinal ganglion cells without activating off-pathway muscarinic receptors (Nano Letters,, April breakthrough paper). Such innovations address longstanding challenges related to ocular drug retention times by creating depot-forming vehicles that gradually release active compounds over extended periods—critical for chronic disease management scenarios requiring consistent dosing schedules over months or years rather than daily administration regimens typical today.

The evolving landscape surrounding b>b>Atropine Sulfate Monohydrate (CAS No.) reflects both historical medical utility and cutting-edge scientific exploration across multiple frontiers—from optimizing existing therapies using advanced formulation strategies down to uncovering entirely new mechanisms through modern analytical tools like single-molecule fluorescence microscopy applied this year at Harvard Medical School labs studying neuronal receptor interactions under live-cell conditions without exogenous labeling agents interference previously seen with older techniques like FRET assays which often required invasive modifications affecting natural physiological states being studied.

• 5452-35-7(cycloheptanamine)
• 6835-16-1(Hyoscyamine Sulfate Dihydrate)
• 614-75-5(2-Hydroxyphenylacetic acid)
• 55-48-1(Atropine sulfate)
• 585-99-9(D-(+)-Melibiose)
• 866926-81-0(Scopolamine Sulfate)
• 620-61-1(L-Hyoscyamine sulfate)
• 73791-47-6(Endo-8-Methyl-8-azabicyclo3.2.1octan-3-yl 3-hydroxy-2-phenylpropanoate sulfate dihydrate(2:1:2))
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)